おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Chinagene Tech
company
About
Chinagene Tech is an ophthalmology clinical genetic diagnosis organization
- 11 - 50
Details
- Last Funding Type
- Corporate Round
- Last Funding Money Raised
- ¥10M
- Industries
- Clinical Trials,Enterprise
- Founded date
- Jan 1, 2016
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Beijing Zhongyin Technology Co., Ltd. is a professional enterprise engaged in the research and development of clinical genetic diagnosis, prevention and gene therapy for hereditary eye diseases. The company's clinical genetic diagnosis platform for hereditary eye diseases can provide fast, accurate, reliable and professional clinical genetic diagnosis services for hereditary ophthalmology patients.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
¥180M
Chinagene Tech has raised a total of
¥180M
in funding over 2 rounds. Their latest funding was raised on
Mar 30, 2022 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 30, 2022 | Series A | ¥100M | 1 |
|
— | Detail |
| Mar 29, 2021 | Seed | ¥70M | 2 |
Lotus Lake Ventures
|
— | Detail |
| Mar 6, 2019 | Corporate Round | ¥10M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
2
4
Chinagene Tech is funded by 4 investors.
Longqian Capital
and Lotus Lake Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series A |
|
Lotus Lake Ventures
|
Yes | Seed |
Longmen Capital
|
— | Seed |
|
|
— | Corporate Round |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
